» Articles » PMID: 33736628

Cervical Cancer in Women Under 30 years of Age in Norway: a Population-based Cohort Study

Overview
Publisher Biomed Central
Date 2021 Mar 19
PMID 33736628
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We compared women with incident cervical cancer under the age of 30 with older women with regard to stage, morphology, screening history and cervical cancer mortality in a population-based cohort study.

Methods: We included data from the Cancer Registry of Norway. Incidence rates (per 100,000 women-years) were calculated and joinpoint regression was used to analyse trends. The Nelson-Aalen cumulative hazard function for risk of cervical cancer death during a 15-year follow-up was displayed. The hazard ratios (HRs) of cervical cancer mortality with 95% confidence intervals (CIs) were derived from Cox regression models.

Results: The incidence of cervical cancer in women under the age of 30 has almost tripled since the 1950s, with the steepest increase during 1955-80 (with an annual percentage change (APC) of 7.1% (95%CI 4.4-9.8)) and also an increase after 2004 (3.8% (95%CI -1.3-9.2)). Out of 21,160 women with cervical cancer (1953-2013), 5.3% were younger than 30 years. A lower proportion of younger women were diagnosed at more advanced stages and a slightly higher proportion were diagnosed with adenocarcinoma and adenosquamous carcinoma comparing women above 30 years. The cumulative risk of cervical cancer death was lower for patients under the age of 30. However, the difference between the age groups decreased over time. The overall adjusted HR of cervical cancer mortality was 0.69 (95% CI 0.58-0.82) in women diagnosed under the age of 30 compared to older women.

Conclusion: There has been an increase in cervical cancer incidence in women under the age of 30. Cervical cancer in younger women was not more advanced at diagnosis compared to older women, and the cervical cancer mortality was lower.

Citing Articles

Radiomics analysis based on multiparametric magnetic resonance imaging for differentiating early stage of cervical cancer.

Wu F, Zhang R, Li F, Qin X, Xing H, Lv H Front Med (Lausanne). 2024; 11:1336640.

PMID: 38371508 PMC: 10869616. DOI: 10.3389/fmed.2024.1336640.


Incidence and survival of gynecologic cancer including cervical, uterine, ovarian, vaginal, vulvar cancer and gestational trophoblastic neoplasia in Korea, 1999-2019: Korea Central Cancer Registry.

Yun B, Park E, Ha J, Lee J, Lee K, Lee T Obstet Gynecol Sci. 2023; 66(6):545-561.

PMID: 37953552 PMC: 10663396. DOI: 10.5468/ogs.23208.


Colposcopy referral rates post-introduction of primary screening with human papillomavirus testing: evidence from a large British Columbia cohort study.

Gottschlich A, Gondara L, Smith L, Anderson J, Cook D, Krajden M Lancet Reg Health Am. 2023; 26:100598.

PMID: 37786399 PMC: 10542010. DOI: 10.1016/j.lana.2023.100598.


Age-Specific Trends of Invasive Cervical Cancer Incidence in British Columbia, Canada, 1971-2017.

Raveinthiranathan N, Simkin J, Donken R, Ogilvie G, Smith L, van Niekerk D Curr Oncol. 2023; 30(8):7692-7705.

PMID: 37623038 PMC: 10453046. DOI: 10.3390/curroncol30080557.


Epidemiology of cervical cancer in elderly women: Analysis of incidence, treatment, and survival using German registry data.

Neumeyer S, Tanaka L, Liang L, Klug S Cancer Med. 2023; 12(16):17284-17295.

PMID: 37403686 PMC: 10501271. DOI: 10.1002/cam4.6318.


References
1.
Elfstrom K, Arnheim-Dahlstrom L, von Karsa L, Dillner J . Cervical cancer screening in Europe: Quality assurance and organisation of programmes. Eur J Cancer. 2015; 51(8):950-68. DOI: 10.1016/j.ejca.2015.03.008. View

2.
Harper D, DeMars L . HPV vaccines - A review of the first decade. Gynecol Oncol. 2017; 146(1):196-204. DOI: 10.1016/j.ygyno.2017.04.004. View

3.
Nygard J, Skare G, Thoresen S . The cervical cancer screening programme in Norway, 1992-2000: changes in Pap smear coverage and incidence of cervical cancer. J Med Screen. 2002; 9(2):86-91. DOI: 10.1136/jms.9.2.86. View

4.
Bjorge T, Gunbjorud A, Langmark F, Skare G, Thoresen S . Cervical mass screening in Norway--510,000 smears a year. Cancer Detect Prev. 1994; 18(6):463-70. View

5.
Landy R, Birke H, Castanon A, Sasieni P . Benefits and harms of cervical screening from age 20 years compared with screening from age 25 years. Br J Cancer. 2014; 110(7):1841-6. PMC: 3974083. DOI: 10.1038/bjc.2014.65. View